2016年8月
The Efficacy of Rituximab in High-risk Renal Transplant Recipients
ACTA MEDICA OKAYAMA
- 巻
- 70
- 号
- 4
- 開始ページ
- 295
- 終了ページ
- 297
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.18926/AMO/54507
- 出版者・発行元
- OKAYAMA UNIV MED SCHOOL
Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
- リンク情報
- ID情報
-
- DOI : 10.18926/AMO/54507
- ISSN : 0386-300X
- ORCIDのPut Code : 43365884
- Web of Science ID : WOS:000384748600011